BR1019

DRUG2 trials

Sponsors

Boryung Pharmaceutical Co., Ltd

Conditions

Essential HypertensionType 2 DiabetesType 2 Diabetes Mellitus

Phase 1

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1019 and Co-administration of BR1019-1 and BR1019-2

CompletedNCT06226727

Boryung Pharmaceutical Co., LtdEssential Hypertension, Type 2 Diabetes Mellitus

Start: 2024-02-14End: 2024-03-31Updated: 2024-04-02

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1019 and Co-administration of BR1019-3 and BR1019-2 in Healthy Volunteers

CompletedNCT06636877

Boryung Pharmaceutical Co., LtdEssential Hypertension, Type 2 Diabetes

Start: 2024-10-23End: 2024-12-11Updated: 2024-12-13